TB 10-drug DiaMOND compendium

Our goal was to use systematic drug combination data from in vitro studies to prioritize drug combinations for in vivo study. We used DiaMOND (DOI: 10.1126/sciadv.1701881) to systematically measure drug combination interactions and potencies against Mycobacterium tuberculosis (Erdman strain). This dataset includes all 1-, 2-, and 3-way combinations of a 10-drug set of antibiotics in eight different in vitro models. With these data, we demonstrated that treatment outcomes in two important preclinical mouse models could be predicted using signatures of drug interaction and potency metrics. File 1 (Data cube) includes the antibiotics, in vitro models, time points, and dose-response metrics. File 2 (IC90) includes the 90% inhibitory concentration of the 10 antibiotics in each in vitro model at the terminal time point. File 3 (Abbreviations) includes abbreviations and descriptions used in the Data cube and IC90 files. These data and more detailed descriptions of the experiments and analysis are in Larkins-Ford et al 2021.

本研究的宗旨在于，通过运用体外实验的系统化药物组合数据，对适用于体内研究的药物组合进行优先级排序。本研究采用DiaMOND（DOI: 10.1126/sciadv.1701881）系统评估药物组合对结核分枝杆菌（Erdman株）的相互作用及其效力。本数据集涵盖了包括抗生素在内的10种药物在八种不同体外模型中的1-、2-及3-方式组合。基于这些数据，我们证明了利用药物相互作用特征及其效力指标，能够预测两种关键的前临床小鼠模型的治疗结果。文件1（数据立方体）包含了抗生素、体外模型、时间点和剂量反应指标。文件2（IC90）包括了在终端时间点，每个体外模型中10种抗生素的90%抑制浓度。文件3（缩写）包含了数据立方体和IC90文件中使用的缩写及其描述。关于实验和分析的更详细信息可见于Larkins-Ford等人的2021年论文。